Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Inclusion Criteria Concurrent Medication: Allowed: * Maintenance therapy for opportunistic infections. Patients must have: * HIV infection. * Kaposi's sarcoma that has relapsed or progressed. * Mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral Kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these three conditions). * NO active acute opportunistic infections requiring treatment with myelosuppressive antibiotics (maintenance for OIs is permitted). * Consent of parent or guardian if less than 18 years of age. NOTE: * This study is approved for prisoner participation. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Other active malignancies except basal cell carcinoma of the skin, or carcinoma in situ of the cervix. * Grade 3 or worse peripheral neuropathy. * Altered mental status that would prevent informed consent or prevent study compliance. Patients with the following prior condition are excluded: Neuropsychiatric history. Prior Medication: Excluded: * Prior etoposide. * Any other anti-KS drugs within 14 days prior to study entry. * Any investigational drug other than antiretrovirals within 14 days prior to study entry. * Any prior investigational agent, if given as the ONLY prior treatment for KS. Prior Treatment: Excluded: * Radiation therapy within 7 days prior to study entry. Continued alcohol consumption or continued intravenous drug use that would impair ability to comply with study requirements.